Leadership
Chris Boshoff has been with Pfizer more than 10 years and has led oncology R&D and the integration of Seagen. He will succeed Mikael Dolsten, who will depart after leading R&D for nearly 15 years.
But the expected nominee brings little experience running a large government organization or with the policy and budget challenges confronting Medicare and Medicaid.
Following Phase III safety and cash problems, Inventiva has its eye on lanifibranor becoming the second oral agent approved in NASH. Former Intercept CEO Mark Pruzanski is advising the effort.
Novo Nordisk India MD talks to Scrip about what to expect when Wegovy arrives in India and the local trajectory of Rybelsus. The Danish group also shared findings of a study around obesity.
Recent moves in the industry include C-suite changes at Coya Therapeutics, Kancera and Verrica Pharmaceuticals, which acquires chief financial officer from Aceragen.
Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.
Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.
CEO Albert Bourla said Starboard Value’s push for change at Pfizer is coming 15 months late as the company is already executing a five-point plan to cut costs and pivot on strategy.
Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting
Recent moves in the industry include changes at the top at enGene Holdings, which also acquires chief technology officer from Albireo Pharma.
Positive data on its anti-TIGIT antibody belrestotug meant ITeos provided one of the biggest stories at ESMO this year. CEO Michel Detheux told Scrip there was much more to come from the US-headquartered biotech founded in Belgium.
CEO of Sumitomo Pharma America unit, Adele M. Gulfo, draws from experiences working across companies including Pfizer, to advise on go-to-market strategies for a portfolio across primary care to rare disease.
Sanofi’s EVP (general medicines), Olivier Charmeil, talks about pharma’s evolving go-to-market strategies that enmesh a more personalized, data-driven approach, why the medical, legal, and regulatory (MLR) review process needs to be faster and also impressive learnings from Amazon, Netflix and Ikea around building customer experience.
In a video interview, Nandini Piramal, chairperson of Piramal Pharma, speaks with Scrip about a focus on on-patent products, an integrated ADC offering, a measured approach to the proposed BIOSECURE Act and the company’s strategy to double revenue to about $2bn
The latest reorganization comes after a mid-stage pipeline asset failed in Alzheimer’s disease and Parkinson’s disease.
Recent moves in the industry include changes at the top at Defence Therapeutics, Trevena and Neurocrine Biosciences, plus Alpha Cognition gets a new chief Financial officer.
CEO Nicolas Poirier talked to Scrip about the development plans for two late-stage assets: a therapeutic cancer vaccine and an IL-7 antagonist for ulcerative colitis.
Axcynsis is developing a derivative of the chemotherapy agent Yondelis as a new payload, which the Singapore venture will first apply to a Claudin 6-targeting ADC it plans to take into a Phase I trial in the US, its chairman, CEO and founder tells Scrip in an interview.
Recent moves in the industry include C-suite changes at Cybin, Biomarin and Nuvation Bio, plus Novita Pharmaceuticals gets a new chief executive officer.
Syngene’s CEO talks to Scrip about how the firm is deepening capabilities in areas like ADCs, PROTACs and why the US Inflation Reduction Act may not necessarily shrink outsourced small molecule work. The executive also shares his view on the China ‘rebalancing’ trend amid geopolitical tensions and the US BIOSECURE Act.